Outlook Therapeutics is a late clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a complex, technically challenging and commercially attractive monoclonal antibody, or mAb, for various ophthalmic indications.
Would you like to join our team?
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Read More
| Name | Domain | Purpose | Expiry | Type |
|---|---|---|---|---|
| wpl_user_preference | outlooktherapeutics.com | WP GDPR Cookie Consent Preferences | 1 year | HTTP |
| Name | Domain | Purpose | Expiry | Type |
|---|---|---|---|---|
| _ga | outlooktherapeutics.com | Google Universal Analytics long-time unique user tracking identifier. | 2 years | HTTP |
| _gid | outlooktherapeutics.com | Google Universal Analytics short-time unique user tracking identifier. | 1 days | HTTP |
| _gat | outlooktherapeutics.com | Google Analytics tracking cookie. | Session | HTTP |
| sc_is_visitor_unique | outlooktherapeutics.com | StatCounter unique visitor tracking cookie. | 2 years | HTTP |
| is_unique | statcounter.com | StatCounter unique visitor tracking cookie. | 5 years | HTTP |
| Name | Domain | Purpose | Expiry | Type |
|---|---|---|---|---|
| is_visitor_unique | statcounter.com | --- | 2 years | --- |
| _ga_94N37D3KG5 | outlooktherapeutics.com | --- | 2 years | --- |
